CLOs on the Move

Youth Alternatives Ingraham

www.yimaine.org

 
Youth Alternatives Ingraham is a South Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Community Health Center of Snohomish County

Community Health Center of Snohomish County (CHC) is a non-profit, Federally Qualified Community Health Center providing medical, dental, pharmacy, behavioral health, and additional ancillary services to nearly 70,000 individuals with 243,049 visits in 2021. For over 35 years, CHC has provided services to Snohomish County residents who face barriers to health care with the mission to provide our diverse community with access to high-quality, affordable primary health care. CHC operates seven medical primary care clinics, two medical walk-in clinics, six dental clinics, and five pharmacies, located in convenient locations in Arlington, Edmonds, Everett, and Lynnwood.

ControlRad Systems

ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals.

Arbor Hospice and Home Care

Arbor Hospice & Home Care is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Ann Arbor, MI. To find more information about Arbor Hospice & Home Care, please visit www.arborhospice.org

Esoterix Clinical Trial Services

Esoterix Clinical Trial Services is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caresyntax

Caresyntax is on a mission to make surgery smarter and safer. Our enterprise-grade digital surgery platform delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR.